BioCentury
ARTICLE | Financial News

Tetraphase files for IPO

February 13, 2013 1:41 AM UTC

Tetraphase Pharmaceuticals Inc. (Watertown, Mass.) proposed to raise up to $86.3 million in an IPO underwritten by Barclays; BMO Capital Markets; Stifel; JMP Securities; and Needham. Tetraphase plans to start a Phase III trial of an IV formulation of its lead compound, eravacycline, to treat complicated intra-abdominal infection (cIAI) in 3Q13 and to treat complicated urinary tract infection (cUTI) in 4Q13. ...